NL13
Product Specifications
Target
CDK, PLK, Caspase, Apoptosis, Akt
Related Pathways
Cytoskeletal Signaling, Cell Cycle/Checkpoint, PI3K/Akt/mTOR signaling, Proteases/Proteasome, Apoptosis
Bioactivity
NL13, a Polo-like kinase 4 (PLK4) inhibitor, exhibits an IC 50 value of 2.32 μM. It demonstrates the ability to suppress the viability of PC3 and DU145 prostate cancer cells with respective IC 50 values of 3.51 μM and 2.53 μM. NL13 also inhibits tumor growth in prostate cancer mice. Additionally, it deactivates the AKT signaling pathway by reducing CCNB1/CDK1 levels, leading to G2/M cell cycle arrest and initiating apoptosis through caspase-9/caspase-3 cleavage.
Molecular Formula
C22H19Cl2NO2
Molecular Weight
400.3
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6489305-01 0.2 mL
NR4A1 (S351) (Nuclear Receptor Subfamily 4 Group A Member 1, Orphan Nuclear Receptor TR3, Orphan Nuclear Receptor HMR, Early Response Protein NAK1, Testicular Receptor 3, ST-59, Nur77, GFRP1, HMR, NAK1) (PE)
Sign In for Pricing
View Details MBS6489305-02 5x 0.2 mL
NR4A1 (S351) (Nuclear Receptor Subfamily 4 Group A Member 1, Orphan Nuclear Receptor TR3, Orphan Nuclear Receptor HMR, Early Response Protein NAK1, Testicular Receptor 3, ST-59, Nur77, GFRP1, HMR, NAK1) (PE)
Sign In for Pricing
View Details 
